All In Biotech

Drug Trial Radar · NCT07245771

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Nov 4, 2025

Primary completion

Feb 15, 2027

Study completion Aug 15, 2027

Sponsor

Lead sponsor
Ikaria Bioscience Pty LtdIndustry
Sponsor type
Industry
Collaborators
Shanghai Rona Therapeutics Co., Ltd.
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161 with tirzepatide (overweight and obese subjects)

Conditions

  • Obesity &Amp; Overweight

Interventions

  • RN3161Drug

    Investigational Product

  • Placebo ControlDrug

    0.9% normal saline SC injection

  • TirzepatideDrug

    In Part 3; randomized to either RN3161 + tirzepatide or placebo + tirzepatide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood PressureTime frame: 180 Days
  2. ECG PR intervalTime frame: 180 days
  3. Physical ExaminationTime frame: 180 days
  4. Blood Chemistry LaboratoryTime frame: 180 days
  5. Adverse EventsTime frame: 180 days
  6. Heart RateTime frame: 180 days
  7. ECG QRS ComplexTime frame: 180 days
  8. ECG QT intervalTime frame: 180 days
  9. Blood Hematology LaboratoryTime frame: 180 days
  10. Blood Coagulation LaboratoryTime frame: 180 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.